Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sobrera Pharma AB has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution involves a distinct examiner and 1 distinct art unit. ARCORIA, PAUL JOSEPH is the busiest examiner for the company, managing the 1 pending office action. The focus on a single examiner and art unit for the matter suggests a concentrated legal strategy. This allows for a direct and consistent relationship with ARCORIA, PAUL JOSEPH during the examination process. The 1 distinct art unit provides the specialized technical environment for the pharmaceutical matter.
The Biotechnology & Pharmaceuticals technology area covers the active matter currently pending for the company. Having only a distinct examiner ensures that all feedback is centralized and originates from ARCORIA, PAUL JOSEPH. The 1 distinct art unit indicates that the pending application is being reviewed by a specific group of biotechnology experts. With a single pending office action, the company can focus its resources on resolving the current examiner concerns. This distinct examiner and art unit represent the entirety of the company's current patent office engagement. The pending office action is the sole focus of the company's active prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18863395 | SELECTIVE DOPAMINE INCREASE | ARCORIA, PAUL JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863395 | SELECTIVE DOPAMINE INCREASE | ARCORIA, PAUL JOSEPH | 1629 | §103 | Non-Final OA | — | Pending | Nov 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSobrera Pharma AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul Joseph Arcoria has the most, with 1 of Sobrera Pharma AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
